Nuix's Linkurious Acquisition Leads to 3% to 6% Increase in Fiscal Year 2026 to Fiscal Year 2028 Revenue, Earnings Estimate, Jefferies Says

-- Nuix's (ASX:NXL) fiscal year 2026 to fiscal year 2028 revenue and earnings estimates were increased by 3% to 6% to reflect the addition of Linkurious, Jefferies said in a note on Tuesday.

Nuix's Linkurious acquisition was completed broadly in line with expectations. Despite drawing AU$20 million of debt, the firm is expected to remain in a net cash position.

Jefferies acknowledged the potential cross-sell opportunities and technology enhancements following the acquisition, but added that it was too early to incorporate these into its forecasts.

The investment firm maintained a buy rating on Nuix and a price target of AU$2.20 per share.

Lucid Diagnostics Completes $18 Million Direct Offering of Shares

Lucid Diagnostics (LUCD) said Friday that is has completed its underwritten direct offering of 18 million shares at $1 per share.The company said the offering was anchored by a $15 million investment from a "fundamental" institutional investor with support from a large existing shareholder.Lucid said it plans to use the net proceeds for working capital and general corporate purposes.Price: $1.09, Change: $-0.01, Percent Change: -0.46%

$LUCD

Dover Sees Strong Bookings Growth, Demand Momentum, RBC Capital Markets Says

Dover (DOV) reported a modest Q1 operating beat, with 24% bookings growth and a 1.20x book-to-bill ratio pointing to demand momentum, RBC Capital Markets said in a Thursday note.The firm said bookings strength was broad-based, with all segments posting book-to-bill above 1.10x.RBC highlighted strength in clean energy components, fluid transport, retail fueling, refrigerated door cases, heat exchangers and CO2 refrigeration systems.The firm also said bookings strength suggests upside to Dover's 3% to 5% organic growth guidance. Dover reaffirmed its 2026 adjusted earnings per share guidance of $10.45 to $10.65, and revenue growth outlook of 5% to 7%.RBC raised its price target to $252 from $225, and maintained its sector perform rating on Dover.Price: $229.96, Change: $+1.81, Percent Change: +0.79%

$DOV

Pharvaris Insider Sold Shares Worth $441,726, According to a Recent SEC Filing

Anne Lesage, Chief Early Development Officer, on April 22, 2026, sold 14,700 shares in Pharvaris (PHVS) for $441,726. Following the Form 4 filing with the SEC, Lesage has control over a total of 213,319 common shares of the company, with 56,450 shares held directly and 156,869 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1830487/000119312526176222/xslF345X05/ownership.xmlPrice: $28.49, Change: $+1.20, Percent Change: +4.40%

$PHVS

Related Articles

Lucid Diagnostics Completes $18 Million Direct Offering of Shares

Dover Sees Strong Bookings Growth, Demand Momentum, RBC Capital Markets Says

Pharvaris Insider Sold Shares Worth $441,726, According to a Recent SEC Filing